PortalPublikationenUse of cryopreserved bone marrow in unrelated allogeneic tra...

Use of cryopreserved bone marrow in unrelated allogeneic transplantation.

Standard

Use of cryopreserved bone marrow in unrelated allogeneic transplantation. / Stockschläder, M; Krüger, W; Tom Dieck, A; Horstmann, Martin; Altnöder, M; Löliger, C; Fiedler, W; Hoffknecht, M; Erttmann, Rudolf; Zander, A.

in: BONE MARROW TRANSPL, Jahrgang 17, Nr. 2, 2, 1996, S. 197-199.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stockschläder, M, Krüger, W, Tom Dieck, A, Horstmann, M, Altnöder, M, Löliger, C, Fiedler, W, Hoffknecht, M, Erttmann, R & Zander, A 1996, 'Use of cryopreserved bone marrow in unrelated allogeneic transplantation.', BONE MARROW TRANSPL, Jg. 17, Nr. 2, 2, S. 197-199. <http://www.ncbi.nlm.nih.gov/pubmed/8640166?dopt=Citation>

APA

Stockschläder, M., Krüger, W., Tom Dieck, A., Horstmann, M., Altnöder, M., Löliger, C., Fiedler, W., Hoffknecht, M., Erttmann, R., & Zander, A. (1996). Use of cryopreserved bone marrow in unrelated allogeneic transplantation. BONE MARROW TRANSPL, 17(2), 197-199. [2]. http://www.ncbi.nlm.nih.gov/pubmed/8640166?dopt=Citation

Vancouver

Stockschläder M, Krüger W, Tom Dieck A, Horstmann M, Altnöder M, Löliger C et al. Use of cryopreserved bone marrow in unrelated allogeneic transplantation. BONE MARROW TRANSPL. 1996;17(2):197-199. 2.

Bibtex

@article{70abd4605f7a4b49b2e87c10babb5afd,
title = "Use of cryopreserved bone marrow in unrelated allogeneic transplantation.",
abstract = "Cryopreservation of donor bone marrow can facilitate scheduling allogeneic bone marrow transplantation (BMT) by affording independence of a preset time for donation. Previously, we and others have shown the feasibility of using cryopreserved related allogeneic bone marrow. Here, we report the results of the first 10 patients receiving cryopreserved unrelated bone marrow between 1992 and 1995. All evaluable patients (n = 9) engrafted. Time to reach an absolute neutrophil count (ANC) >0.2 x 10(9)/1 and ANC >0.5 x 10(9)/l was 21.4 +/- 9.1 days and 22.6 +/- 9.2 days, respectively. The incidence of acute GVHD > or = grade II and chronic GVHD was 75 and 20%, respectively. Five of nine evaluable patients were alive 100 days post-transplantation. We conclude that cryopreserved unrelated donor bone marrow may be used for allogeneic transplantation.",
author = "M Stockschl{\"a}der and W Kr{\"u}ger and {Tom Dieck}, A and Martin Horstmann and M Altn{\"o}der and C L{\"o}liger and W Fiedler and M Hoffknecht and Rudolf Erttmann and A Zander",
year = "1996",
language = "Deutsch",
volume = "17",
pages = "197--199",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Use of cryopreserved bone marrow in unrelated allogeneic transplantation.

AU - Stockschläder, M

AU - Krüger, W

AU - Tom Dieck, A

AU - Horstmann, Martin

AU - Altnöder, M

AU - Löliger, C

AU - Fiedler, W

AU - Hoffknecht, M

AU - Erttmann, Rudolf

AU - Zander, A

PY - 1996

Y1 - 1996

N2 - Cryopreservation of donor bone marrow can facilitate scheduling allogeneic bone marrow transplantation (BMT) by affording independence of a preset time for donation. Previously, we and others have shown the feasibility of using cryopreserved related allogeneic bone marrow. Here, we report the results of the first 10 patients receiving cryopreserved unrelated bone marrow between 1992 and 1995. All evaluable patients (n = 9) engrafted. Time to reach an absolute neutrophil count (ANC) >0.2 x 10(9)/1 and ANC >0.5 x 10(9)/l was 21.4 +/- 9.1 days and 22.6 +/- 9.2 days, respectively. The incidence of acute GVHD > or = grade II and chronic GVHD was 75 and 20%, respectively. Five of nine evaluable patients were alive 100 days post-transplantation. We conclude that cryopreserved unrelated donor bone marrow may be used for allogeneic transplantation.

AB - Cryopreservation of donor bone marrow can facilitate scheduling allogeneic bone marrow transplantation (BMT) by affording independence of a preset time for donation. Previously, we and others have shown the feasibility of using cryopreserved related allogeneic bone marrow. Here, we report the results of the first 10 patients receiving cryopreserved unrelated bone marrow between 1992 and 1995. All evaluable patients (n = 9) engrafted. Time to reach an absolute neutrophil count (ANC) >0.2 x 10(9)/1 and ANC >0.5 x 10(9)/l was 21.4 +/- 9.1 days and 22.6 +/- 9.2 days, respectively. The incidence of acute GVHD > or = grade II and chronic GVHD was 75 and 20%, respectively. Five of nine evaluable patients were alive 100 days post-transplantation. We conclude that cryopreserved unrelated donor bone marrow may be used for allogeneic transplantation.

M3 - SCORING: Zeitschriftenaufsatz

VL - 17

SP - 197

EP - 199

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

M1 - 2

ER -